USFDA completes inspection of Lupin’s Nagpur plant

New Delhi: Pharma major Lupin today said the US health regulator has completed inspection of its Nagpur facility without making any observations.

In a BSE filing, Lupin “announced successful completion of an inspection carried out by the United States Food and Drug Administration (USFDA) at its Nagpur facility. The inspection concluded without any observations”.

Lupin said its Nagpur facility manufactures oral solid products.

Shares of Lupin were trading 2.09 per cent higher at Rs 767.50 on BSE.

  • Related Posts

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

    NEW DELHI: Medical technology innovation is entering a new phase, with advanced cardiac implants, incisionless brain surgery, blood-based cancer screening, smart insulin delivery and real-time kidney-function monitoring among the technologies…

    Three arrested after liquor bottles found at pharma firm

    Patna: Three people were arrested and sent to jail after a large quantity of liquor bottles was found at Cellulas Pharma Private Limited in Kankarbagh during a raid by the…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

    The Most Innovative Medical Devices of 2026: Breakthrough Technologies Target Heart Disease, Cancer, Neurological Disorders and Kidney Dysfunction

    Three arrested after liquor bottles found at pharma firm

    Three arrested after liquor bottles found at pharma firm

    NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

    NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

    National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

    National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

    Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

    Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

    Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources

    Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources